Clinical trial · Interventional
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
Melphalan vs Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
NCT03385096CI-TRIAL-00043607unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Autologous Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
| Conditioning | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Busulfan (BU) | Drug | Busulfan | ALIAS |
| Cyclophosphamide (CY) | Drug | Cyclophosphamide | ALIAS |
| Etoposide (VP-16) | Drug | Etoposide | ALIAS |
| Melphalan | Drug | Melphalan | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- BUCY+VP-16
- description
- For MM patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -8 and -6；CY 60 mg/kg/day on days -5 and -4; VP-16 10mg/kg/day on days -3 and -2.
- interventionNames
- Drug: Busulfan (BU)
- Drug: Cyclophosphamide (CY)
- Drug: Etoposide (VP-16)
- type
- ACTIVE_COMPARATOR
- label
- Melphalan
- description
- For MM patients undergoing auto-HSCT，Melphalan conditioning regimen was Melphalan 200mg/m2 on day -2.
- interventionNames
- Drug: Melphalan
Primary outcomes (1)
- measure
- OS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Multiple Myeloma patients * Achieving at least VGPR after chemotherapy, then mobilizing and collecting of peripheral blood stem cells Exclusion Criteria: * Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * Patients with any conditions not suitable for the trial (investigators' decision
References
Publications (0)
Data not yet available
No reference posted for this study.